Millennium Management
MACK

Millennium Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Millennium Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-1,881
Closed -$46K – 4143
2017
Q1 		$46K Buy
+1,881
New +$47.1K ﹤0.01% 3393

Other funds holding MACK

WSL
Western Standard LLC Los Angeles, California $190M AUM 40.88% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return

Millennium Management's MACK Position: Q3 2023 in Review

Millennium Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2023, closing a stake of 10,749 shares — an estimated $132K sold.

Millennium Management first reported a position in MACK in Q2 2013 and held it in 27 quarters. The position peaked at $20.3M in Q4 2014. 63 funds tracked by Wall St. Rank hold MACK as of Q3 2023.

  • Millennium Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
  • Millennium Management sold 10,749 Merrimack Pharmaceuticals, Inc. shares in Q3 2023, an estimated $132K.
  • Millennium Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 27 quarters.
  • Millennium Management's Merrimack Pharmaceuticals, Inc. position peaked at $20.3M in Q4 2014.
  • 63 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2023.

Based on Millennium Management's 13F filing for Q3 2023, filed 14 Nov 2023.